Giuliana Alimena

Giuliana Alimena

UNVERIFIED PROFILE

Are you Giuliana Alimena?   Register this Author

Register author
Giuliana Alimena

Giuliana Alimena

Publications by authors named "Giuliana Alimena"

Are you Giuliana Alimena?   Register this Author

100Publications

2163Reads

38Profile Views

Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors.

Br J Haematol 2018 08 5;182(3):427-429. Epub 2017 Jul 5.

Haematology, Department of Cellular Biotechnologies and Haematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14783DOI Listing
August 2018

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients.

Am J Hematol 2017 Jan 12;92(1):37-41. Epub 2016 Nov 12.

Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Institute of Hematology and Clinical Oncology "L. and A. Seràgnoli", Sant'Orsola-Malpighi University Hospital, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24572DOI Listing
January 2017

Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

Expert Opin Drug Saf 2016 16;15(4):525-33. Epub 2016 Feb 16.

a Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14740338.2016.1145654DOI Listing
December 2016

Early molecular response in chronic myeloid leukemia and halving time: Latest evidences.

Leuk Res 2016 09 1;48:20-5. Epub 2016 Jul 1.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2016.06.010DOI Listing
September 2016

How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.

Expert Opin Pharmacother 2016 Aug 3;17(11):1517-26. Epub 2016 Jun 3.

a Department of Cellular Biotechnologies and Hematology , Sapienza University , Rome , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2016.1190335DOI Listing
August 2016

Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly.

Br J Haematol 2016 07 28;174(1):160-2. Epub 2015 Oct 28.

Department of Haematology and Oncology, Città della Salute e della Scienza Hospital, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13758DOI Listing
July 2016

Sex correlates with differences in long-term outcome in chronic myeloid leukaemia patients treated with imatinib.

Br J Haematol 2016 06 25;173(6):945-6. Epub 2015 Aug 25.

Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13649DOI Listing
June 2016

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.

J Clin Oncol 2016 Mar 25;34(9):972-9. Epub 2016 Jan 25.

Sergio Amadori, Adriano Venditti, and Maria Teresa Voso, Tor Vergata University; Luciana Annino, San Giovanni Addolorata Hospital; Paolo De Fabritiis, St Eugenio Hospital; Giuliana Alimena and Marco Mancini, Sapienza University; Francesca Paoloni, Marco Vignetti, and Paola Fazi, GIMEMA Foundation, Roma; Franco Aversa, University Hospital, Parma; Gainluca Gaidano, University of Eastern Piedmont, Novara; Maurizio Musso, La Maddalena Clinic, Palermo; Carla Mazzone, Annunziata Hospital, Cosenza; Domenico Magro, Pugliese-Ciaccio Hospital, Catanzaro; Safaa Mahmoud Ramadan, European Institute of Oncology, Milano, Italy; Stefan Suciu and Liv Meert, EORTC Headquarters, Brussels; Dominik Selleslag, AZ St Jan, Brugge; Anne Hagemeijer, KULeuven, Leuven; Frédéric Baron, Centre Hospitalier Universitaire, Liège, Belgium; Petra Muus and Theo de Witte, Radboudumc, Nijmegen; and Roel Willemze, University Medical Center, Leiden, the Netherlands.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2016/01/21/JCO.2015.64
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.64.0060
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.64.0060DOI Listing
March 2016

Cutaneous Lesions Anticipating Accelerated Phase of Multidrug Resistant Chronic Myeloid Leukemia Responsive to Ponatinib.

Mediterr J Hematol Infect Dis 2016 20;8(1):e2016016. Epub 2016 Feb 20.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4084/MJHID.2016.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771144PMC
March 2016

Ponatinib in chronic myeloid leukaemia: ready for first-line?

Lancet Haematol 2015 Sep 30;2(9):e352-3. Epub 2015 Jul 30.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome 00161, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(15)00130-1DOI Listing
September 2015

Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?

Expert Rev Hematol 2015 Aug 27;8(4):387-9. Epub 2015 Apr 27.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2015.1041494DOI Listing
August 2015

Erythropoietin treatment in patients with myelodysplastic syndromes and type 2 diabetes.

J Diabetes 2015 Jul 3;7(4):493-6. Epub 2014 Oct 3.

Hematology Unit, Azienda Ospedaliera "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1753-0407.12203DOI Listing
July 2015

The Importance of Body Surface Area at Baseline and during Treatment in Chronic Myeloid Leukemia Patients Treated with Imatinib.

Acta Haematol 2015 11;134(1):57-8. Epub 2015 Apr 11.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000370098DOI Listing
July 2015

Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients.

Am J Hematol 2015 May 30;90(5):E95-6. Epub 2015 Mar 30.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23972DOI Listing
May 2015

Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib.

Am J Hematol 2015 May;90(5):E100-1

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23976DOI Listing
May 2015

Long-term outcome of chronic myeloid leukaemia patients with p210 and p190 co-expression at baseline.

Br J Haematol 2015 Apr 9;169(1):148-50. Epub 2014 Oct 9.

Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13184DOI Listing
April 2015

Firstline treatment for chronic phase chronic myeloid leukemia patients should be based on a holistic approach.

Expert Rev Hematol 2015 Feb 28;8(1):5-7. Epub 2014 Nov 28.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Via Benevento 6, 00161 Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2015.987230DOI Listing
February 2015

How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review.

Leuk Res 2014 Dec 5;38(12):1392-8. Epub 2014 Oct 5.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2014.09.016DOI Listing
December 2014

Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?

Ann Hematol 2014 Nov 7;93(11):1951-2. Epub 2014 May 7.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Via Benevento 6, 00161, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-014-2096-yDOI Listing
November 2014

Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy.

Expert Opin Pharmacother 2014 Aug 3;15(11):1621-30. Epub 2014 Jul 3.

Sapienza University, Department of Cellular Biotechnologies and Hematology , Via Benevento 6, 00161, Rome , Italy +3906857951 ; +390644241984 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2014.936849DOI Listing
August 2014

Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013.

Crit Rev Oncol Hematol 2014 Jun 17;90(3):181-9. Epub 2013 Dec 17.

Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, Orbassano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2013.12.010DOI Listing
June 2014

Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia.

Cancer Lett 2014 May 4;347(1):22-8. Epub 2014 Feb 4.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2014.01.033DOI Listing
May 2014

Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib.

Leuk Lymphoma 2014 Jan 29;55(1):204-6. Epub 2013 May 29.

Department of Cellular Biotechnologies and Hematology, Sapienza University , Rome , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2013.795650DOI Listing
January 2014

Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome.

Blood Transfus 2014 Jan 15;12 Suppl 1:s162-3. Epub 2013 Apr 15.

Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2450/2013.0005-13DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934268PMC
January 2014

Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs.

Mediterr J Hematol Infect Dis 2014 Jan 2;6(1):e2014003. Epub 2014 Jan 2.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4084/MJHID.2014.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894843PMC
January 2014

Imatinib induces body mass changes in women with chronic myeloid leukemia.

Ann Hematol 2013 Nov 12;92(11):1581-2. Epub 2013 Apr 12.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Via Benevento 6, 00161, Rome, Italy,

View Article

Download full-text PDF

Source
http://search.proquest.com/openview/c432d9bd98968fbad8e9ed3d
Web Search
http://link.springer.com/10.1007/s00277-013-1752-y
Publisher Site
http://dx.doi.org/10.1007/s00277-013-1752-yDOI Listing
November 2013

The pros and cons of new prognostic eutos score for chronic myeloid leukemia patients.

Leuk Res 2013 Nov 5;37(11):1436-7. Epub 2013 Sep 5.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2013.08.013DOI Listing
November 2013

"To switch or not to switch: that is the question"-more than 10% of ratio @ 3 months: how to treat chronic myeloid leukemia patients with this response?

Leuk Res 2013 Sep 24;37(9):995-7. Epub 2013 Jun 24.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2013.05.015DOI Listing
September 2013

Efficacy and safety of deferasirox in myelodysplastic syndromes.

Ann Hematol 2013 Jul 17;92(7):863-70. Epub 2013 Feb 17.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Via Benevento 6, 00161, Rome, Italy,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-013-1703-7DOI Listing
July 2013

Management options for refractory chronic myeloid leukemia: considerations for the elderly.

Drugs Aging 2013 Jul;30(7):467-77

Department of Cellular Biotechnologies and Hematology, Sapienza University, Via Benevento 6, 00161, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40266-013-0085-9DOI Listing
July 2013

The role of comorbidities in chronic myeloid leukemia.

Leuk Res 2013 Jul 28;37(7):729-30. Epub 2013 Apr 28.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2013.04.001DOI Listing
July 2013

Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors.

Leuk Res 2013 Jun 7;37(6):713-20. Epub 2013 Mar 7.

Department of Cellular Biotechnology and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2013.01.021DOI Listing
June 2013

Systematic review of dasatinib in chronic myeloid leukemia.

Onco Targets Ther 2013 27;6:257-65. Epub 2013 Mar 27.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S35360DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615898PMC
April 2013

Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far?

Leuk Res 2013 Feb 20;37(2):204-5. Epub 2012 Nov 20.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2012.10.023DOI Listing
February 2013

Suboptimal response in chronic myeloid leukemia patients treated with imatinib: early identification and new therapeutic challenges.

Cancer Lett 2012 Dec 6;325(1):18-25. Epub 2012 Jun 6.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2012.05.032DOI Listing
December 2012

How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantages.

Cancer Lett 2012 Sep 23;322(2):127-32. Epub 2012 Mar 23.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2012.03.021DOI Listing
September 2012

Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: who's afraid of the big bad wolf?

Leuk Res 2012 Jul 5;36(7):813-4. Epub 2012 Apr 5.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2012.03.010DOI Listing
July 2012

Combination of azacitidine and ESA in myelodysplastic patients: the need for prospective studies.

Leuk Res 2012 Jun 17;36(6):682-3. Epub 2012 Mar 17.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2012.02.020DOI Listing
June 2012

Neutropenia at baseline could indicate poor prognosis in low/intermediate risk myelodysplastic syndrome patients.

Leuk Res 2012 May 4;36(5):546-7. Epub 2012 Feb 4.

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2012.01.003DOI Listing
May 2012

Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.

Clin Adv Hematol Oncol 2012 Apr;10(4):266-8

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
April 2012

Isolated myeloid sarcoma without bone marrow involvement.

Clin Adv Hematol Oncol 2012 Jan;10(1):66-7

Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

View Article

Download full-text PDF

Source
January 2012